Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV

Upfront anti-EGFR therapy represents the standard of care for patients with left-sided, MSS/pMMR, RAS and BRAF wild-type mCRC. Molecular “hyperselection” may maximize the therapeutic index of EGFR inhibition by detecting additional resistance alterations.

Source: European Journal of Cancer - October 19, 2023 Category: Cancer & Oncology Authors: Filippo Pietrantonio, Francesca Bergamo, Daniele Rossini, Filippo Ghelardi, Maria Caterina De Grandis, Marco Maria Germani, Giulia Barsotti, Vincenzo Formica, Giovanni Luca Frassineti, Giorgia Boscolo, Saverio Cinieri, Samantha Di Donato, Lorenzo Antonuzz Tags: Original Research Source Type: research